Product Information
DROSP-EE-LEVOMEF 3-0.02-0.451 is a generic product labeled by Sandoz Inc., priced at $1.3823 per EA under NDC 00781407515. Its NADAC has been published 502 times since Feb 22, 2017.
FDA first approved this application on Sep 24, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
DROSP-EE-LEVOMEF 3-0.02-0.451
Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calciumManufacturer
Sandoz Inc.NDC
00781407515
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Authorized Generic (NDA)
FDA Application
NDA022532FDA Approved
9/24/2010
TE Code
AB
On Market Since
10/12/2016
Price Statistics
The NADAC for DROSP-EE-LEVOMEF 3-0.02-0.451 has been published 502 times since Feb 22, 2017, and over the history we have for it it has declined 66.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3823 per EA |
|---|---|
| All-time high | $4.5285 (Apr 13, 2022) |
| All-time low | $1.2304 (Jul 17, 2024) |
| 52-week high | $1.6322 |
| 52-week low | $1.2523 |
| Median price | $3.1992 |
| Average price | $2.9574 |
| Largest weekly change | -47.8% (Apr 17, 2024) |
| Weeks tracked | 502 |
| Tracking since | Feb 22, 2017 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sandoz Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DROSP-EE-LEVOMEF 3-0.02-0.451?
The current National Average Drug Acquisition Cost (NADAC) for DROSP-EE-LEVOMEF 3-0.02-0.451, manufactured by Sandoz Inc., is $1.3823 per EA (NDC 00781407515), effective Sep 30, 2026.
How has the price of DROSP-EE-LEVOMEF 3-0.02-0.451 changed over time?
Over the history we have for it, the NADAC for DROSP-EE-LEVOMEF 3-0.02-0.451 has declined 66.1%. It has been tracked across 502 weekly CMS publications since Feb 22, 2017.
What are the highest and lowest recorded NADAC prices for DROSP-EE-LEVOMEF 3-0.02-0.451?
Since Feb 22, 2017, the NADAC for DROSP-EE-LEVOMEF 3-0.02-0.451 has ranged from a low of $1.2304 (Jul 17, 2024) to a high of $4.5285 (Apr 13, 2022), with a median of $3.1992 per EA.
Are there cheaper alternatives to DROSP-EE-LEVOMEF 3-0.02-0.451?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DROSP-EE-LEVOMEF 3-0.02-0.451 in a comparable dosage form, but none are currently priced below it.
Who manufactures DROSP-EE-LEVOMEF 3-0.02-0.451?
DROSP-EE-LEVOMEF 3-0.02-0.451 (NDC 00781407515) is labeled by Sandoz Inc., and CMS classifies it as a generic product.